a Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy , Cairo University , Cairo , Egypt.
b Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy , October 6 University , Giza , Egypt.
J Liposome Res. 2019 Mar;29(1):73-85. doi: 10.1080/08982104.2018.1430831. Epub 2018 Feb 6.
Skin is considered the most accessible organ of the body because of its underlying capillary network. However, stratum corneum (SC), the upper most layer of skin, represents major diffusional barrier for most drugs. Hence, the use of edge activators (EAs) in designing novel elastic vesicles is hypothesized to impart their lipid bilayer with ultra-flexibility to trespass SC by high self-optimizing deformability. To confirm this hypothesis, this work aimed at developing novel bilosomes by modulating conventional niosomal composition using different bile salts as EAs and investigating their superiority over niosomes for transdermal delivery of diacerein (DCN), as model drug. Bilosomes were prepared by thin film hydration (TFH) technique according to full 3.2 factorial design to select the optimal formulation using Design-Expert software. The optimal bilosomes (B6) showed nanosized vesicles (301.65 ± 17.32 nm) and 100.00 ± 0.00 % entrapment efficiency. Ex vivo permeation studies and in vivo evaluation revealed that B6 exhibited superior permeation and drug retention capacity compared to the conventional niosomal formulation and drug suspension. Furthermore, B6 was subjected to in vivo histopathological study using male Wistar rats which ensured its safety for topical application. Overall, the results confirmed the hypothesized superiority of bilosomes over niosomes for enhancing DCN flux across the skin.
皮肤因其潜在的毛细血管网络而被认为是身体最容易接近的器官。然而,皮肤的最上层——角质层(SC),是大多数药物的主要扩散屏障。因此,在设计新型弹性囊泡时使用边缘激活剂(EAs),假设可以赋予其脂质双层超高的自优化变形能力,从而突破 SC。为了验证这一假设,本工作旨在通过使用不同的胆汁盐作为 EAs 来调节常规的非离子囊泡的组成,来开发新型的双体囊泡,并研究其在双氯芬酸钠(DCN)经皮传递中的优越性,DCN 是模型药物。双体囊泡通过薄膜水化(TFH)技术按照完全 3.2 因子设计来制备,使用 Design-Expert 软件选择最佳配方。最佳的双体囊泡(B6)显示出纳米尺寸的囊泡(301.65 ± 17.32nm)和 100.00 ± 0.00%的包封效率。体外渗透研究和体内评价表明,B6 与常规的非离子囊泡制剂和药物混悬剂相比,表现出优越的渗透和药物滞留能力。此外,B6 还通过雄性 Wistar 大鼠进行了体内组织病理学研究,这确保了其用于局部应用的安全性。总的来说,结果证实了双体囊泡在增强 DCN 跨皮通量方面优于非离子囊泡的假设。